{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T19:29:23Z","timestamp":1769714963229,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T00:00:00Z","timestamp":1760659200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100013278","name":"EU Joint Programme \u2013 Neurodegenerative Disease Research","doi-asserted-by":"publisher","award":["643417"],"award-info":[{"award-number":["643417"]}],"id":[{"id":"10.13039\/100013278","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["CNS Drugs"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s40263-025-01237-w","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T14:05:22Z","timestamp":1760709922000},"page":"233-246","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["The Medication Patterns of Spinocerebellar Ataxia Type 3 Mutation Carriers Enrolled in the ESMI Cohort"],"prefix":"10.1007","volume":"40","author":[{"given":"Patrick","family":"Silva","sequence":"first","affiliation":[]},{"given":"Marina A.","family":"Costa","sequence":"additional","affiliation":[]},{"given":"Laetitia","family":"Gaspar","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Dur\u00e3es","sequence":"additional","affiliation":[]},{"given":"In\u00eas","family":"Cunha","sequence":"additional","affiliation":[]},{"given":"Joana A","family":"Ribeiro","sequence":"additional","affiliation":[]},{"given":"Cristina","family":"Janu\u00e1rio","sequence":"additional","affiliation":[]},{"given":"B\u00e1rbara","family":"Oliveiros","sequence":"additional","affiliation":[]},{"given":"Jeannette","family":"H\u00fcbener-Schmid","sequence":"additional","affiliation":[]},{"given":"Jennifer","family":"Faber","sequence":"additional","affiliation":[]},{"given":"Mafalda","family":"Raposo","sequence":"additional","affiliation":[]},{"given":"Manuela","family":"Lima","sequence":"additional","affiliation":[]},{"given":"Hector","family":"Garcia-Moreno","sequence":"additional","affiliation":[]},{"given":"Paola","family":"Giunti","sequence":"additional","affiliation":[]},{"given":"Lukas","family":"Beichert","sequence":"additional","affiliation":[]},{"given":"Ludger","family":"Sch\u00f6ls","sequence":"additional","affiliation":[]},{"given":"Bart P.","family":"van de Warrenburg","sequence":"additional","affiliation":[]},{"given":"Jeroen","family":"de Vries","sequence":"additional","affiliation":[]},{"given":"Andreas","family":"Thieme","sequence":"additional","affiliation":[]},{"given":"Kathrin","family":"Reetz","sequence":"additional","affiliation":[]},{"given":"Heike","family":"Jacobi","sequence":"additional","affiliation":[]},{"given":"Jon","family":"Infante","sequence":"additional","affiliation":[]},{"given":"Thomas","family":"Klockgether","sequence":"additional","affiliation":[]},{"name":"ESMI Study Group","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Ferreira","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Rosa","sequence":"additional","affiliation":[]},{"given":"Carlos","family":"Gonzalez","sequence":"additional","affiliation":[]},{"given":"Cristina","family":"Gonzalez-Robles","sequence":"additional","affiliation":[]},{"given":"Dagmar","family":"Timmann","sequence":"additional","affiliation":[]},{"given":"Friedrich","family":"Erdlenbruch","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Lemos","sequence":"additional","affiliation":[]},{"given":"Jo\u00e3o","family":"Vasconcelos","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds","family":"Teves","sequence":"additional","affiliation":[]},{"given":"Paula","family":"Pires","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Lopes","sequence":"additional","affiliation":[]},{"given":"Pedro","family":"Coelho","sequence":"additional","affiliation":[]},{"given":"Teresa","family":"Kay","sequence":"additional","affiliation":[]},{"given":"Lu\u00eds Pereira","family":"de Almeida","sequence":"additional","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4076-7516","authenticated-orcid":false,"given":"Magda M.","family":"Santana","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,10,17]]},"reference":[{"issue":"3","key":"1237_CR1","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1159\/000358801","volume":"42","author":"L Ruano","year":"2014","unstructured":"Ruano L, Melo C, Silva MC, et al. The global epidemiology of hereditary ataxia and spastic paraplegia: a systematic review of prevalence studies. Neuroepidemiology. 2014;42(3):174\u201383.","journal-title":"Neuroepidemiology"},{"key":"1237_CR2","unstructured":"Prevalence of rare diseases: bibliographic data, in Rare Diseases collection, O.R. Series, Editor. 2023."},{"key":"1237_CR3","doi-asserted-by":"publisher","first-page":"2615","DOI":"10.1007\/978-3-030-23810-0_104","volume-title":"Handbook of the Cerebellum and Cerebellar Disorders","author":"M Yamada","year":"2022","unstructured":"Yamada M, et al. Neuropathology of ataxias. In: Manto MU, et al., editors. Handbook of the Cerebellum and Cerebellar Disorders. Cham: Springer International Publishing; 2022. p. 2615\u201337."},{"issue":"1","key":"1237_CR4","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1038\/s41572-019-0074-3","volume":"5","author":"T Klockgether","year":"2019","unstructured":"Klockgether T, Mariotti C, Paulson HL. Spinocerebellar ataxia. Nat Rev Dis Primers. 2019;5(1):24.","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"1237_CR5","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1002\/acn3.51370","volume":"8","author":"SM Brooker","year":"2021","unstructured":"Brooker SM, Edamakanti CR, Akasha SM, et al. Spinocerebellar ataxia clinical trials: opportunities and challenges. Ann Clin Transl Neurol. 2021;8(7):1543\u201356.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"1237_CR6","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1186\/s13023-019-1013-9","volume":"14","author":"R de Silva","year":"2019","unstructured":"de Silva R, Greenfield J, Cook A, et al. Guidelines on the diagnosis and management of the progressive ataxias. Orphanet J Rare Dis. 2019;14(1):51.","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"1237_CR7","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1212\/WNL.0000000000005055","volume":"90","author":"TA Zesiewicz","year":"2018","unstructured":"Zesiewicz TA, Wilmot G, Kuo SH, et al. Comprehensive systematic review summary: treatment of cerebellar motor dysfunction and ataxia: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. Neurology. 2018;90(10):464\u201371.","journal-title":"Neurology"},{"issue":"2","key":"1237_CR8","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1007\/s12311-013-0531-6","volume":"13","author":"W Ilg","year":"2014","unstructured":"Ilg W, Bastian AJ, Boesch S, et al. Consensus paper: management of degenerative cerebellar disorders. Cerebellum. 2014;13(2):248\u201368.","journal-title":"Cerebellum"},{"issue":"11","key":"1237_CR9","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1212\/01.wnl.0000219042.60538.92","volume":"66","author":"T Schmitz-Hubsch","year":"2006","unstructured":"Schmitz-Hubsch T, du Montcel ST, Baliko L, et al. Scale for the assessment and rating of ataxia: development of a new clinical scale. Neurology. 2006;66(11):1717\u201320.","journal-title":"Neurology"},{"issue":"3","key":"1237_CR10","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1007\/s12311-012-0421-3","volume":"12","author":"H Jacobi","year":"2013","unstructured":"Jacobi H, Rakowicz M, Rola R, et al. Inventory of Non-Ataxia Signs (INAS): validation of a new clinical assessment instrument. Cerebellum. 2013;12(3):418\u201328.","journal-title":"Cerebellum"},{"key":"1237_CR11","doi-asserted-by":"crossref","unstructured":"Rai SN, Singh P, Steinbusch HWM, et al. The role of vitamins in neurodegenerative disease: an update. Biomedicines. 2021; 9(10).","DOI":"10.3390\/biomedicines9101284"},{"key":"1237_CR12","doi-asserted-by":"crossref","unstructured":"Orywal K, Socha K, Iwaniuk P, et al. Vitamins in the prevention and support therapy of neurodegenerative diseases. Int J Mol Sci. 2025;26(3).","DOI":"10.3390\/ijms26031333"},{"key":"1237_CR13","unstructured":"Schuelke M. Ataxia with vitamin E deficiency, in GeneReviews, M.P. Adam, et al., Editors. 1993: Seattle (WA)."},{"issue":"4","key":"1237_CR14","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1017\/S0029665107005812","volume":"66","author":"P Mason","year":"2007","unstructured":"Mason P. One is okay, more is better? Pharmacological aspects and safe limits of nutritional supplements. Proc Nutr Soc. 2007;66(4):493\u2013507.","journal-title":"Proc Nutr Soc"},{"issue":"11 Suppl 2","key":"1237_CR15","doi-asserted-by":"publisher","first-page":"S28","DOI":"10.1016\/j.amjmed.2008.09.011","volume":"121","author":"MA Raskind","year":"2008","unstructured":"Raskind MA. Diagnosis and treatment of depression comorbid with neurologic disorders. Am J Med. 2008;121(11 Suppl 2):S28-37.","journal-title":"Am J Med"},{"issue":"9","key":"1237_CR16","doi-asserted-by":"publisher","first-page":"3456","DOI":"10.1007\/s00415-021-10516-7","volume":"268","author":"R Maas","year":"2021","unstructured":"Maas R, Killaars S, van de Warrenburg BPC, et al. The cerebellar cognitive affective syndrome scale reveals early neuropsychological deficits in SCA3 patients. J Neurol. 2021;268(9):3456\u201366.","journal-title":"J Neurol"},{"issue":"8","key":"1237_CR17","doi-asserted-by":"publisher","first-page":"4363","DOI":"10.1007\/s00415-022-11071-5","volume":"269","author":"A Thieme","year":"2022","unstructured":"Thieme A, Faber J, Sulzer P, et al. The CCAS-scale in hereditary ataxias: helpful on the group level, particularly in SCA3, but limited in individual patients. J Neurol. 2022;269(8):4363\u201374.","journal-title":"J Neurol"},{"issue":"4","key":"1237_CR18","doi-asserted-by":"publisher","first-page":"1411","DOI":"10.1007\/s12311-023-01651-0","volume":"23","author":"LP Selvadurai","year":"2024","unstructured":"Selvadurai LP, Perlman SL, Ashizawa T, et al. The Cerebellar Cognitive Affective\/Schmahmann Syndrome Scale in spinocerebellar ataxias. Cerebellum. 2024;23(4):1411\u201325.","journal-title":"Cerebellum"},{"issue":"5","key":"1237_CR19","doi-asserted-by":"publisher","first-page":"870","DOI":"10.1002\/mds.23698","volume":"26","author":"T Schmitz-Hubsch","year":"2011","unstructured":"Schmitz-Hubsch T, Coudert M, Tezenas du Montcel S, et al. Depression comorbidity in spinocerebellar ataxia. Mov Disord. 2011;26(5):870\u20136.","journal-title":"Mov Disord"},{"key":"1237_CR20","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.parkreldis.2015.11.021","volume":"22","author":"RY Lo","year":"2016","unstructured":"Lo RY, Figueroa KP, Pulst SM, et al. Depression and clinical progression in spinocerebellar ataxias. Parkinsonism Relat Disord. 2016;22:87\u201392.","journal-title":"Parkinsonism Relat Disord"},{"key":"1237_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nbd.2021.105278","volume":"152","author":"J Pereira-Sousa","year":"2021","unstructured":"Pereira-Sousa J, Ferreira-Lomba B, Bellver-Sanchis A, et al. Identification of the 5-HT(1A) serotonin receptor as a novel therapeutic target in a C. elegans model of Machado-Joseph disease. Neurobiol Dis. 2021;152:105278.","journal-title":"Neurobiol Dis"},{"issue":"1","key":"1237_CR22","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1097\/00002826-200401000-00005","volume":"27","author":"A Takei","year":"2004","unstructured":"Takei A, Fukazawa T, Hamada T, et al. Effects of tandospirone on \u201c5-HT1A receptor-associated symptoms\u201d in patients with Machado-Josephe disease: an open-label study. Clin Neuropharmacol. 2004;27(1):9\u201313.","journal-title":"Clin Neuropharmacol"},{"issue":"4","key":"1237_CR23","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1007\/s12311-010-0199-0","volume":"9","author":"A Takei","year":"2010","unstructured":"Takei A, Hamada S, Homma S, et al. Difference in the effects of tandospirone on ataxia in various types of spinocerebellar degeneration: an open-label study. Cerebellum. 2010;9(4):567\u201370.","journal-title":"Cerebellum"},{"issue":"1\u20132","key":"1237_CR24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.jns.2007.04.019","volume":"260","author":"M Assadi","year":"2007","unstructured":"Assadi M, Campellone JV, Janson CG, et al. Treatment of spinocerebellar ataxia with buspirone. J Neurol Sci. 2007;260(1\u20132):143\u20136.","journal-title":"J Neurol Sci"},{"issue":"12","key":"1237_CR25","doi-asserted-by":"publisher","first-page":"1767","DOI":"10.1001\/archneur.64.12.1767","volume":"64","author":"MC Franca","year":"2007","unstructured":"Franca MC, D\u2019Abreu A, Friedman JH, et al. Chronic pain in Machado-Joseph disease: a frequent and disabling symptom. Arch Neurol. 2007;64(12):1767\u201370.","journal-title":"Arch Neurol"},{"key":"1237_CR26","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s40734-016-0047-6","volume":"3","author":"P Termsarasab","year":"2016","unstructured":"Termsarasab P, Thammongkolchai T, Frucht SJ. Medical treatment of dystonia. J Clin Mov Disord. 2016;3:19.","journal-title":"J Clin Mov Disord"},{"issue":"4","key":"1237_CR27","doi-asserted-by":"publisher","first-page":"655","DOI":"10.5664\/jcsm.8308","volume":"16","author":"V Dokkedal-Silva","year":"2020","unstructured":"Dokkedal-Silva V, Kim LJ, Morelhao PK, et al. Use of clonazepam in REM sleep behavior disorder: association with fall-related injuries and alternative treatments. J Clin Sleep Med. 2020;16(4):655\u20136.","journal-title":"J Clin Sleep Med"},{"key":"1237_CR28","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/125273","volume":"2015","author":"H Park","year":"2015","unstructured":"Park H, Kim HJ, Jeon BS. Parkinsonism in spinocerebellar ataxia. Biomed Res Int. 2015;2015:125273.","journal-title":"Biomed Res Int"},{"key":"1237_CR29","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/1471-2377-11-131","volume":"11","author":"C Bettencourt","year":"2011","unstructured":"Bettencourt C, Santos C, Coutinho P, et al. Parkinsonian phenotype in Machado-Joseph disease (MJD\/SCA3): a two-case report. BMC Neurol. 2011;11:131.","journal-title":"BMC Neurol"},{"issue":"4","key":"1237_CR30","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1002\/ana.410380422","volume":"38","author":"PJ Tuite","year":"1995","unstructured":"Tuite PJ, Rogaeva EA, St. George-Hyslop PH, et al. Dopa-responsive parkinsonism phenotype of Machado-Joseph disease: confirmation of 14q CAG expansion. Ann Neurol. 1995;38(4):684\u20137.","journal-title":"Ann Neurol"},{"issue":"2","key":"1237_CR31","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1002\/mds.10322","volume":"18","author":"C Buhmann","year":"2003","unstructured":"Buhmann C, Bussopulos A, Oechsner M. Dopaminergic response in Parkinsonian phenotype of Machado-Joseph disease. Mov Disord. 2003;18(2):219\u201321.","journal-title":"Mov Disord"},{"issue":"2","key":"1237_CR32","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1007\/s00415-022-11441-z","volume":"270","author":"H Hengel","year":"2023","unstructured":"Hengel H, Martus P, Faber J, et al. The frequency of non-motor symptoms in SCA3 and their association with disease severity and lifestyle factors. J Neurol. 2023;270(2):944\u201352.","journal-title":"J Neurol"},{"issue":"3","key":"1237_CR33","volume":"2011","author":"H Scholz","year":"2011","unstructured":"Scholz H, Trenkwalder C, Kohnen R, et al. Dopamine agonists for restless legs syndrome. Cochrane Database Syst Rev. 2011;2011(3):CD006009.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"1237_CR34","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.smrv.2013.03.004","volume":"18","author":"M Hornyak","year":"2014","unstructured":"Hornyak M, Scholz H, Kohnen R, et al. What treatment works best for restless legs syndrome? Meta-analyses of dopaminergic and non-dopaminergic medications. Sleep Med Rev. 2014;18(2):153\u201364.","journal-title":"Sleep Med Rev"},{"issue":"3","key":"1237_CR35","doi-asserted-by":"publisher","first-page":"193","DOI":"10.2340\/16501977-2211","volume":"49","author":"P Ertzgaard","year":"2017","unstructured":"Ertzgaard P, Campo C, Calabrese A. Efficacy and safety of oral baclofen in the management of spasticity: a rationale for intrathecal baclofen. J Rehabil Med. 2017;49(3):193\u2013203.","journal-title":"J Rehabil Med"}],"container-title":["CNS Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01237-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40263-025-01237-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40263-025-01237-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,29]],"date-time":"2026-01-29T09:00:17Z","timestamp":1769677217000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40263-025-01237-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,17]]},"references-count":35,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["1237"],"URL":"https:\/\/doi.org\/10.1007\/s40263-025-01237-w","relation":{},"ISSN":["1172-7047","1179-1934"],"issn-type":[{"value":"1172-7047","type":"print"},{"value":"1179-1934","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,17]]},"assertion":[{"value":"26 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LPA has received funding from Servier and UCB. LS has served on advisory boards for VICO Therapeutics, VIGIL Neuroscience, and Novartis. BvdW has served on advisory boards or as a consultant for VICO Therapeutics, Biogen, and Biohaven Pharmaceuticals. PG has received grants and honoraria for advisory board participation from Vico Therapeutics, honoraria for an advisory board from Triplet Therapeutics, grants and personal fees from Reata Pharmaceutical, and grants from Wave Life Sciences. KR has received honoraria for presentations or advisory board participation from Biogen, Eisai, Lilly, and Roche. TK has received consulting fees from Biogen, UCB, and Vico Therapeutics. JF has received consultancy honoraria from Vico Therapeutics. PS, MAC, LG, JD, IC, JAR, CJ, BO, JHS, MR, ML, HGM, LB, JV, AT, HJ, JI, and MMS have no potential conflicts of interest to report.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"This study was conducted by ESMI with approval from local ethical committees at all centers, and in accordance with the Helsinki Declaration of 1964 and its later amendments, as well as local institutional ethics committee requirements. An exception to the Declaration was that the study was not prospectively or retrospectively registered, as it was a noninterventional observational analysis of existing registry data for which trial registration is not otherwise required.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Written informed consent was obtained from all participants prior to enrollment. Participants were informed of the aims of the study, the voluntary nature of their participation, and their right to withdraw at any time without prejudice. Confidentiality of all personal and clinical data was strictly maintained.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Most of the data that support the findings of this study are available in the Supplementary Material. Additional data are available from the corresponding author upon reasonable request.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Materials"}},{"value":"The code used for data processing and statistical analyses in this study is available from the corresponding author upon reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Design and conceptualization of the study: PS, MMS, and LPA. Subject recruitment\/acquisition of participant data: PS, LG, JD, IC, JAR, CJ, JHS, JF, MR, ML, HGM, PG, LB, LS, BvdW, JdV, AT, KR, HJ, JI, TK, and MMS. Statistical analysis of data: PS, MAC, BO, and MMS. Drafting of the manuscript: PS and MMS. Revision of the manuscript: PS, LG, JD, JHS, MR, ML, HGM, LS, BvdW, JdV, AT, KR, HJ, JI, TK, and MMS. All authors read and approved the final submitted manuscript and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contribution"}}]}}